Standard dosing algorithms could be responsible for the higher rates of thyrotoxicosis among older women vs men prescribed levoythroxine.

The FDA has approved Isturisa (osilodrostat) for the treatment of endogenous hypercortisolemia in adults with Cushing syndrome for whom surgery is not an option or has not been curative.